AMAG Pharmaceuticals’ $300 Million Convertible Senior Notes Offering

Goodwin advised AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) in the completion of its $300 million aggregate principal amount of 3.25% convertible senior notes due 2022 in an…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Ambrogio Visconti

This content is for Standard 1 Year members only.
Login Join Now